A pathophysiology diagram illustrating the signaling pathway and functional activation of dendritic cells (DCs) in Allergic Rhinitis (AR) compared to Healthy Controls (HC). The visual workflow begins with an immature DC, containing Ten-eleven translocation (TET) enzymes in the nucleus. Two experimental pathways for phenotypic activation are shown: allergen challenge (depicting a dust mite icon) and TET1-shRNA treatment. Both interventions result in the maturation of the DC, characterized by increased surface expression of costimulatory molecules including CD80, CD83, CD86, CD40, and HLA-DR. The final stage demonstrates functional activation through the co-culture of these activated DCs with CD4+ Th cells. The diagram highlights that these interactions lead to the differentiation of CD4+ T cell subsets, specifically showing the modulation of activated T regulatory cells (aTreg) and the persistent presence of TETs. This infographic summarizes how the loss or inhibition of TET1 in atopic DCs mimics allergen-induced maturation and influences subsequent T-cell mediated immune responses.

A pathophysiology diagram illustrating the three stages of allergic rhinitis: Early phase, Late phase, and Chronic phase. The 'Early phase' section depicts a mast cell activated by allergens binding to IgE on its surface receptors, triggering the release of inflammatory mediators including proteases, histamine, arachidonic acid (AA) metabolites, growth factors, and cytokines/chemokines. Associated vascular changes such as increased blood vessel permeability and nerve stimulation are shown. The 'Late phase' section demonstrates leukocyte recruitment and extravasation through a blood vessel wall, featuring an eosinophil, monocyte, basophil, neutrophil, and a migrating lymphocyte. It also shows a Th2 cell secreting interleukins IL-4, IL-5, IL-9, and IL-13. The 'Chronic phase' section illustrates the persistent presence and coexistence of degranulating eosinophils and mast cells in the inflamed tissue. This diagram provides a clinical overview of the immunological cascade and cellular interactions involved in allergic airway inflammation and tissue remodeling.

This medical infographic illustrates the pathophysiological landscape of Allergic Rhinitis (AR) in the context of COVID-19 susceptibility. A central human figure representing an AR patient is shown inhaling COVID-19 viral particles. Four circular callouts detail specific immunological and pharmacological factors influencing disease outcomes. The diagram highlights that AR patients exhibit 'low-level' ACE2 receptors on epithelial cells and 'low-level' Interferons (IFN), both of which are factors that may limit viral entry and replication. Conversely, the image depicts 'high-level' eosinophils, which are noted for their protective role in antiviral host defense. The final callout represents treatment strategies, labeled 'Anti-inflammatory Medicine,' featuring icons of a mortar and pestle with botanicals alongside a medical bottle, reflecting the use of both inhaled corticosteroids and traditional medicine. The illustration serves as an educational summary of why patients with allergic rhinitis might experience different susceptibility or severity levels when infected with SARS-CoV-2.

A pathophysiology diagram illustrating the multifactorial etiology of Allergic Rhinitis (AR). The graphic is organized into three major thematic bubbles converging on a central 'Allergic rhinitis' node, which is accompanied by icons of a nasal spray and an affected human profile. 1. Genetic Factors: Depicts a DNA double helix and lists specific susceptibility genes including SDAD1, Various Interleukins (IL1R1, IL13, IL18, IL21/IL2, IL23R, IL12RB1, IL27), Chemokines (CXCL9, CXCL10, CXCL11, RANTES), and others like SMAD3, GATA3, and HLA-DQ. 2. Environmental Factors: Features icons representing cigarette smoke (smoking), a dog (pet dander), a flower (pollen), a virus (infection), and the sun (climate change/ozone), alongside air pollution and toxicants. 3. Epigenetic Factors: Highlights mechanisms such as DNA methylation, histone acetylation, and miRNA level alterations, visually represented by chromatin structures with 'Me' (methylation) tags. This educational infographic summarizes the complex interplay between hereditary predisposition, external triggers, and gene-expression modifications in the pathogenesis of respiratory allergic disease.

This comparison clinical photograph depicts the efficacy of topical antihistamine formulations on induced skin reactions in a rabbit model. The visual is organized into two rows representing time points: 'At Zero Mint' and 'After 15 Mints', subdivided into three experimental groups (A, B, and C). Group A evaluates a novel Ebastine emulgel, Group B serves as a positive control using a standard antihistamine (Benadryl), and Group C acts as the untreated negative control. At 0 minutes, all groups show histamine-induced erythema and wheal formation, with Group C exhibiting the most severe, raised, and inflamed lesion. Surface markings in blue and pink demarcate treatment zones. At 15 minutes, Group A and Group B demonstrate a visible reduction in the intensity and area of erythema, indicating effective drug absorption and inhibition of the H1-receptor-mediated allergic response. In contrast, Group C maintains significant, persistent inflammation and redness. The images illustrate the clinical progression of allergic skin lesions and the therapeutic effect of topical emulgel formulations on inflammatory symptoms like redness and swelling.

Summary : This figure presents a clinical recommendation regarding the use of modern 2nd generation H1-antihistamines as first-line treatment for urticaria, supported by strong consensus and evidence. flowchart: # Recommendation Statement : • "Should modern 2nd generation H1-antihistamines be used as first-line treatment of urticaria?" (header). • Recommendation: "We recommend a 2nd generation H1-antihistamine as first-line treatment for all types of urticaria." # Consensus and Evidence : • Strong consensus (indicated by "↑↑" and the phrase "Strong consensus¹"). • Evidence- and consensus-based (reference to an Evidence Report). # Visual Elements : • Central green vertical bar with two upward arrows ("↑↑") indicating strong recommendation. • Text boxes to the left (recommendation) and right (consensus/evidence) of the green bar. Analysis : • The figure visually and textually communicates a strong, evidence-based consensus to use modern 2nd generation H1-antihistamines as the first-line treatment for all types of urticaria. • The use of bold, boxed text and arrows emphasizes the strength and clarity of the recommendation.

The image displays Saturation Transfer Difference (STD) NMR spectra illustrating competition assays between different influenza A hemagglutinin (HA) subtypes and receptor analogs. Four vertically stacked spectra compare the binding affinities of H1 HA, H5-V HA, H5-Q HA, and H9 HA toward two sialic acid analogs: 2,3-sialyllactose (3'SL, human-like) and 2,6-sialyllactose (6'SL, avian-like). The x-axis represents the 1H chemical shift in ppm, ranging from 2.6 to 2.8, specifically focusing on the H3eq resonance peaks. In the H1 HA spectrum, a dominant peak at 2.67 ppm signifies a higher binding preference for 6'SL. Conversely, the H5-V HA spectrum shows a prominent peak at 2.73 ppm, indicating a strong preference for 3'SL. The H5-Q and H9 HA spectra exhibit dual binding patterns with relatively equal peak intensities for both 3'SL and 6'SL, though with varying levels of signal resolution. This diagnostic visualization is used in virology and pharmacology to determine host-receptor specificity and pandemic potential of different influenza strains.